Does #baricitinib affect #fatigue in RA patients? 👉🏼Results from RA-BEAM and RA-BEACON 👉🏼4mg baricitinib significantly reduced fatigue, starting week 16, compared to placebo 👉🏼Effect independent of disease activity in active RA Abs#1235 #ACR21 @RheumNow https://t.co/0SKhUKJHd7 https://t.co/R76wc56u6I

• Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two…

FDA Update session: Proven Benefit of Baricitinib in Hospitalized COVID-19 from the ACT2 and COV-BARRIER Studies, showing it does not need to be given with Remdesivir (4 mg qd maz 14days) #ACR21 https://t.co/r6crPtu3ZH

#RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G

• A Multinational, Prospective, Observational Study in Patients with Rheumatoid A…

Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM

Wk 12 disease activity predicts wk 24/26 remission/low disease activity with #upadacitinib 15mg in MTX-naïve or inadequate responders to MTX and/or TNFi pts. ≥50% improvement in SJC/TJC at Wk 12 was assoc with wk 24/26 remission/low disease activity. Abs#1237 #ACR21 @RheumNow https://t.co/PAaCe5MAcu

Baricitinib for *relapsing* GCA (Th1+Th17) w abbreviated steroid wean (15-22w) Despite being tougher to treat: 100% off steroids at 24w 93% off steroids at 52w no ischemic Sx promising as another GCA Rx option! (post-cessation 4pts flared) @MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk